Streptococcus pneumoniae remains an important cause of pneumonia and invasive bacterial disease, primarily meningitis and sepsis. The greatest burden of disease occurs in low-and middle-income countries, and the risk of serious pneumococcal disease peaks at the extreme ages of life. Young children are at highest risk, but older adults and people with immuno-compromising conditions also suffer high rates of pneumococcal disease.
Resources & Publications
In Chile and Peru, the Sabin Vaccine Institute worked in partnership with the Pan American Health Organization to assess the impact and effectiveness of pneumococcal conjugate vaccine (PCV) on hospitalizations and deaths due to childhood pneumonia, following PCV introduction into the national immunization programs of these countries. Studies demonstrating the effect of PCV immunization on pneumococcal morbidity and mortality in middle income countries with high disease burden are historically scarce.
The 4th Regional Pneumococcal Symposium was held in Johannesburg, South Africa on 2-3 March 2009. Over 185 people from 38 countries, including 23 African countries, attended the two-day meeting in South Africa. During the symposium, participants heard presentations and discussed topics ranging from pneumococcal epidemiology to country perspectives on vaccine introduction and disease surveillance.
The 3rd Regional Pneumococcal Symposium held in Istanbul, Turkey on February 13-14, 2008, brought together 200 participants from Turkey, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Greece, Bulgaria and Romania as well as officials from the World Health Organization and representatives from multilateral agencies and pharmaceutical companies to discuss the latest advances of Pneumococcal vaccines.